Relyea Zuckerberg Hanson LLC Increases Stock Holdings in Stryker Corporation $SYK

Relyea Zuckerberg Hanson LLC boosted its position in shares of Stryker Corporation (NYSE:SYK) by 2.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,634 shares of the medical technology company’s stock after purchasing an additional 54 shares during the period. Relyea Zuckerberg Hanson LLC’s holdings in Stryker were worth $1,042,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Nuveen LLC purchased a new position in Stryker during the 1st quarter worth $558,075,000. Price T Rowe Associates Inc. MD raised its holdings in Stryker by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock worth $4,515,847,000 after purchasing an additional 1,021,496 shares in the last quarter. Alliancebernstein L.P. lifted its position in shares of Stryker by 66.7% during the first quarter. Alliancebernstein L.P. now owns 1,373,142 shares of the medical technology company’s stock valued at $511,152,000 after buying an additional 549,643 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Stryker by 1.1% in the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock worth $12,306,572,000 after buying an additional 361,136 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in Stryker by 13.1% during the first quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after acquiring an additional 261,058 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Stryker news, insider Viju Menon sold 500 shares of the company’s stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the transaction, the insider owned 12,511 shares of the company’s stock, valued at $4,886,921.71. This represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the sale, the director directly owned 3,222,108 shares in the company, valued at $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. BTIG Research reissued a “buy” rating on shares of Stryker in a research report on Monday, July 14th. Wells Fargo & Company upped their price target on shares of Stryker from $435.00 to $445.00 and gave the company an “overweight” rating in a research note on Friday, August 1st. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Redburn Partners set a $420.00 price objective on shares of Stryker in a research note on Thursday, September 18th. Finally, Rothschild & Co Redburn assumed coverage on shares of Stryker in a research report on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price for the company. Fifteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $430.33.

Stryker Trading Up 1.1%

Shares of SYK stock opened at $370.59 on Monday. Stryker Corporation has a 1-year low of $329.16 and a 1-year high of $406.19. The company has a market cap of $141.68 billion, a price-to-earnings ratio of 49.08, a PEG ratio of 2.67 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The stock has a 50 day simple moving average of $382.81 and a 200-day simple moving average of $378.96.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping analysts’ consensus estimates of $3.07 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The company had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same period in the prior year, the business posted $2.81 earnings per share. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be given a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Stryker’s dividend payout ratio (DPR) is presently 44.50%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.